Clinical Trials Logo

Filter by:
NCT ID: NCT05424718 Active, not recruiting - HIV Clinical Trials

MyPEEPS Mobile for Young Transgender Men

Start date: June 16, 2023
Phase: N/A
Study type: Interventional

The proposed MyPEEPS intervention for young transgender men is a novel and evidence-driven intervention using mobile technology to deliver HIV prevention information to high risk youth. The final product will be the basis for conducting a large-scale efficacy study in this population.

NCT ID: NCT05424367 Active, not recruiting - Obesity Clinical Trials

Food Environment, Food Insecurity, and Health Behaviors in NH Hispanics

Start date: October 1, 2021
Phase:
Study type: Observational

This telephone-based survey included adults of Hispanic/Latino background residing in New Hampshire (NH). Information on food security and access, food environment, and health status and behaviors was collected through validated questionnaires. This project addresses the need for assessment of barriers to nutrition and health during COVID-19 in this population.

NCT ID: NCT05424354 Active, not recruiting - Wounds and Injuries Clinical Trials

Acute Partial Thickness Burn Study Comparing Transforming Powder Dressing to Standard of Care Dressing

Start date: May 26, 2022
Phase: Phase 4
Study type: Interventional

This study is being performed to assess the effectiveness of Altrazeal(R) Transforming Powder Dressing (TPD) in patients with partial thickness burns compared to the current standard of care (SOC) dressing. Adult men and women 18-65 years old who are hospitalized with an acute (meaning the burn injury occurred less than 36 hours prior to enrollment in the study) partial thickness burn wound, less than 20 percent of total body surface area may be considered. Subjects will be randomized in a 1:1 ratio to either SOC or TPD. Subjects will be followed for up to 28 days after enrollment.

NCT ID: NCT05424276 Active, not recruiting - Parkinson Disease Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease

Start date: May 15, 2023
Phase: Phase 2
Study type: Interventional

This study investigates the safety and tolerability of drug IkT-148009 in untreated Parkinson's disease volunteers (30 to 80 years old). It also looks at the pharmacokinetics of IkT-148009 in the body and evaluates the effect of IkT-148009 on motor and non-motor features of the disease. This 12 week study is designed to be 3:1 randomized across 3 doses of IkT-148009 or placebo. Each participant will self-administer one of 3 doses or placebo of IkT-148009 once daily (QD) with food for 12 weeks. For more information, visit our website: www.the201trial.com

NCT ID: NCT05424042 Active, not recruiting - Aging Clinical Trials

Health, Aging and Later-Life Outcomes

HALLO-P
Start date: July 5, 2022
Phase: N/A
Study type: Interventional

The purpose of this pilot research is to test the feasibility of two interventions focused on either reducing total calorie intake or reducing the total time that calories are ingested each day in older adults. Participation in this research will involve visits to our clinic for testing and weekly intervention visits (in-person or remote depending on group assignment) for nine months with total participation lasting about a year.

NCT ID: NCT05423756 Active, not recruiting - Clinical trials for Skin and Soft Tissue (SST) Infection

INSPIRE Trial for Skin and Soft Tissue Infections

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

The INSPIRE Skin and Soft Tissue Infection trial is a cluster-randomized controlled trial of HCA Healthcare hospitals comparing routine empiric antibiotic stewardship practices with real-time, precision medicine computerized physician order entry (CPOE) smart prompts providing the probability that a non-critically ill adult admitted with skin and soft tissue infection is infected with a resistant pathogen. Note: enrolled "subjects" represent 102 individual HCA Healthcare hospitals that have been randomized into 92 clusters. Hospitals were grouped into the same randomization cluster if they shared campuses or antibiotic stewardship staff.

NCT ID: NCT05423743 Active, not recruiting - Clinical trials for Abdominal (ABD) Infection

INSPIRE Trial for Abdominal Infections

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

The INSPIRE Abdominal Infection Trial is a cluster-randomized controlled trial of HCA Healthcare hospitals comparing routine empiric antibiotic stewardship practices with real-time, precision medicine computerized physician order entry (CPOE) smart prompts providing the probability that a non-critically ill adult admitted with abdominal infection is infected with a resistant pathogen. Note: enrolled "subjects" represent 102 individual HCA Healthcare hospitals that have been randomized into 92 clusters. Hospitals were grouped into the same randomization cluster if they shared campuses or antibiotic stewardship staff.

NCT ID: NCT05423379 Active, not recruiting - Clinical trials for Coronary Artery Disease

XIENCE Skypoint Large Vessel Post Approval Study

SPIRIT XLV PAS
Start date: September 14, 2022
Phase:
Study type: Observational

SPIRIT XLV PAS is a prospective, single arm, multi-center, US and OUS post-approval observational study to evaluate the continued safety and effectiveness of the XIENCE Skypoint Large Vessel Everolimus Eluting Coronary Stent System (EECSS) Large Vessel (LV) sizes (diameter 4.5 mm and 5.0 mm) during commercial use in a real-world setting.

NCT ID: NCT05422768 Active, not recruiting - PTSD Clinical Trials

PTSD Clinical Team Research Clinic (PCT Research Clinic)

Start date: November 16, 2020
Phase:
Study type: Observational

Part of the IRB_00136053 study was to look at the effectiveness of Warrior Renew and Warrior Renew+EAL interventions. Furthermore, demographic information on Veteran participants will be analyzed.

NCT ID: NCT05422222 Active, not recruiting - Cystic Fibrosis Clinical Trials

Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age

Start date: June 21, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the pharmacokinetics, safety, tolerability and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants with at least 1 triple combination responsive (TCR) mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.